JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
